Table 1.

Summary of exposure in Japanese patients for the exposure‐response safety analysis

Summary exposure, µg/mL	Geometric mean (CV%)		% Difference	Median (P05, P95)
	240 mg Q2W	3 mg/kg Q2W		240 mg Q2W	3 mg/kg Q2W
Cavgd28	44.6 (21.4)	32.5 (20.6)	37.2	44.8 (31.6, 61.7)	32.8 (21.9, 45.2)
Cmind28	38.4 (27.7)	27.9 (25.8)	37.6	38.9 (23.5, 59.5)	29.3 (16.5, 41.3)
Cmax1	76.1 (21.0)	55.3 (18.3)	37.6	75.4 (54.6, 108.0)	55.0 (40.7, 73.4)

Cavgd28, nivolumab concentration over the first 28 d; Cmax1, peak concentration after the first dose; Cmind28, trough concentration at day 28; CV, coefficient of variation; P05, fifth percentile; P95, 95th percentile; Q2W, every 2 wk.